Working… Menu
Trial record 13 of 23 for:    "Undifferentiated Pleomorphic Sarcoma" | "Antibiotics, Antitubercular"

Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00410462
Recruitment Status : Unknown
Verified July 2010 by European Organisation for Research and Treatment of Cancer - EORTC.
Recruitment status was:  Active, not recruiting
First Posted : December 13, 2006
Last Update Posted : August 8, 2014
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC

Brief Summary:

RATIONALE: Drugs used in chemotherapy, such as brostallicin and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This randomized phase II trial is studying the side effects and how well brostallicin or doxorubicin works as first-line therapy in treating patients with relapsed, refractory, or metastatic soft tissue sarcoma.

Condition or disease Intervention/treatment Phase
Ovarian Cancer Sarcoma Small Intestine Cancer Drug: brostallicin Drug: doxorubicin hydrochloride Phase 2

Detailed Description:



  • Determine the activity and safety of brostallicin vs doxorubicin hydrochloride as first-line therapy in patients with relapsed, refractory, or metastatic soft tissue sarcoma.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating and age(younger than 60 years vs 60 years and over). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive brostallicin IV over 10 minutes on day 1.
  • Arm II: Patients receive doxorubicin hydrochloride IV over 10 minutes on day 1. In both arms, treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed at 30 days and then every 12 weeks thereafter.

PROJECTED ACCRUAL: A total of 108 patients will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 118 participants
Allocation: Randomized
Primary Purpose: Treatment
Official Title: Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma
Study Start Date : October 2006
Actual Primary Completion Date : September 2008

Primary Outcome Measures :
  1. Six-month progression-free survival, in terms of complete response, partial response, or no change

Secondary Outcome Measures :
  1. Overall progression-free survival
  2. Objective tumor response
  3. Safety (CTCAE v 3.0)
  4. Duration of response
  5. Overall survival

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed high- or intermediate-grade malignant soft tissue sarcoma* of 1 of the following cellular types:

    • Adipocytic (e.g., liposarcoma dedifferentiated, myxoid/round cell, pleomorphic, mixed-type, not otherwise specified)
    • Fibroblastic (e.g., adult fibrosarcoma, myxofibrosarcoma, or sclerosing epithelioid fibrosarcoma)
    • So-called fibrohistiocytic (e.g., pleomorphic malignant fibrous histiocytoma [MFH], giant cell MFH, or inflammatory MFH)
    • Leiomyosarcoma
    • Malignant glomus tumors
    • Skeletal muscle (e.g., rhabdomyosarcoma, alveolar, or pleomorphic)
    • Vascular (e.g., epithelioid hemangioendothelioma or angiosarcoma)
    • Uncertain differentiation (e.g., synovial, epithelioid, alveolar soft part, clear cell, desmoplastic small round cell, extra-renal rhabdoid, malignant mesenchymoma, perivascular epithelioid cell tumor [PEComa], or intimal sarcoma)
    • Malignant peripheral nerve sheath tumors
    • Malignant solitary fibrous tumors
    • Undifferentiated soft tissue sarcomas not otherwise specified
    • Other types of sarcoma if approved by the study coordinator NOTE: *Includes malignant tumors of non-organ origin and skin and uterine leiomyosarcoma
  • The following tumor types are excluded:

    • Embryonal rhabdomyosarcoma
    • Chondrosarcoma
    • Osteosarcoma
    • Ewing tumors/primitive neuroectodermal tumor (PNET)
    • Gastrointestinal stromal tumors
    • Dermatofibrosarcoma protuberans
    • Inflammatory myofibroblastic sarcoma
    • Neuroblastoma
    • Malignant mesothelioma
    • Mixed mesodermal tumors of the uterus
  • Relapsed, refractory, and/or metastatic disease incurable by surgery or radiotherapy
  • Measurable disease
  • Must have formalin fixed paraffin-embedded tumor blocks and representative hematoxylin/eosin slides available for histological central review
  • No symptomatic or known CNS metastases


  • At least 60 years of age OR ≥ 18 years of age if patient is not suitable for intensive combination chemotherapy treatments
  • WHO performance status 0-1
  • Absolute neutrophil count > 2,000/mm³
  • Platelet count > 100,000/mm³
  • Bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • AST and ALT ≤ 2.5 times ULN
  • Alkaline phosphatase ≤ 2.5 times ULN
  • Creatinine clearance ≥ 60 mL/min
  • No serious cardiac illness within the past 6 months, including, but not limited to the following:

    • History of documented congestive heart failure
    • High-risk uncontrolled arrhythmias
    • Angina pectoris requiring antianginal medication
    • Clinically significant valvular heart disease
    • Evidence of transmural infarction on ECG
    • Poorly-controlled hypertension (e.g., systolic blood pressure [BP] > 180 mm Hg or diastolic BP > 100 mm Hg)
  • Normal 12-lead ECG
  • LVEF normal by MUGA or echocardiogram
  • No other malignancy within the past 3 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix or breast
  • No other serious and/or unstable medical condition, illness, or lab abnormality that would preclude study participation
  • No psychiatric illness or familial, social, or geographical condition that would preclude study compliance
  • No active uncontrolled infection
  • No known AIDS positivity
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception


  • No prior chemotherapy regimen for advanced or metastatic disease (neoadjuvant and adjuvant therapy allowed)
  • No concurrent sargramostim (GM-CSF) except in cases of febrile neutropenia
  • No other concurrent anticancer therapy or investigational agents, including any of the following:

    • Chemotherapy
    • Biological response modifiers
    • Hormone therapy
    • Immunotherapy
  • No other concurrent clinical treatment trial participation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00410462

Layout table for location information
Leiden University Medical Center
Leiden, Netherlands, 2300 RC
Sponsors and Collaborators
European Organisation for Research and Treatment of Cancer - EORTC
Layout table for investigator information
Study Chair: Hans Gelderblom, MD, PhD Leiden University Medical Center

Publications of Results:
Gelderblom H, Blay J, Seddon BM, et al.: Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An EORTC Soft Tissue and Bone Sarcoma Group randomized phase II study. [Abstract] J Clin Oncol 28 (Suppl 15) A-10037, 2010.

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: European Organisation for Research and Treatment of Cancer - EORTC Identifier: NCT00410462     History of Changes
Other Study ID Numbers: EORTC-62061
First Posted: December 13, 2006    Key Record Dates
Last Update Posted: August 8, 2014
Last Verified: July 2010
Keywords provided by European Organisation for Research and Treatment of Cancer - EORTC:
adult malignant fibrous histiocytoma
recurrent adult soft tissue sarcoma
stage IV adult soft tissue sarcoma
adult liposarcoma
adult fibrosarcoma
adult leiomyosarcoma
adult rhabdomyosarcoma
adult alveolar soft-part sarcoma
adult malignant mesenchymoma
adult angiosarcoma
adult epithelioid sarcoma
adult neurofibrosarcoma
adult synovial sarcoma
recurrent uterine sarcoma
stage IV uterine sarcoma
ovarian sarcoma
small intestine leiomyosarcoma
recurrent small intestine cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Antibiotics, Antineoplastic
Intestinal Neoplasms
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms by Site
Gastrointestinal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Liposomal doxorubicin
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action